Cannabit Ltd., will be the exclusive supplier of medical cannabis for clinical research into treatment for opioid addiction. The company will be entitled to exclusive marketing of the treatment method in Israel, Germany and England too. The study will be done using a patent for an addiction treatment method that is currently undergoing registration by JFM Technology Holdings LLC, for which Opiostop has received an exclusive, unlimited license, under the U.S.FDA's fast-track. The U.S. company Opiostop will provide all the financing, the submission of the patent and follow-up submissions, will be responsible for the performance and financing of the clinical trial in the United States, and will see to getting all the licenses for importing into the United States.